- Tarceva - $564.2 million
- Xeloda - $647.6 million
- Velcade - $692.7 million
- Erbitux - $703.3 million
- Alimta - $1.04 billion
- Eloxatin - $1.2 billion
- Gleevec - $1.51 billion
- Herceptin - $1.66 billion
- Avastin - $2.66 billion
- Rituxan - $3 billion
- Top 10 Best-selling Cancer Drugs
- Top 10 Pharma CEO Salaries of 2011
- Robert Parkinson - Baxter
- Lamberto Andreotti - Bristol-Myers Squibb
- John Martin - Gilead
- Joseph Jimenez - Novartis
- John Lechleiter - Eli Lilly
- Kevin Sharer - Amgen
- Robert Coury - Mylan
- Miles White - Abbott Laboratories
THE LIBRARY: WEBINAR
Getting the most PoC data in Phase I cancer studies
The hunt for proof-of-concept data is steadily moving upstream in the clinic. Join FierceBiotech on June 12th as three clinical trial experts tackle the question of how you can best design a Phase I study to get a readout on efficacy. Topics will include: enrollment, dosing and the best possible use of biomarkers for experimental cancer drugs. Register Today!
EVENTS
- USP Supply Chain Integrity Workshop May 22-23 — Rockville, MD
- 2012 PDA/FDA Joint Regulatory ConferenceSeptember 10-12 — Baltimore, MD (Baltimore Marriott Waterfront Hotel)
- 2012 PDA ICH Q10 Workshop: Expectations of Operations & Executive ManagementSeptember 12-13 — Baltimore, MD (Baltimore Marriott Waterfront Hotel)
Latest Commentary